BiotechTube

[14C]-Nanatinostat + Nanatinostat (free base) tablets in combination with Valganciclovir + Nanatinostat mesylate tablets in combination with Valganciclovir + Single-agent Nanatinostat (free base) tablets

Phase 1Terminated
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Cancer

Conditions

Advanced Cancer

Trial Timeline

Feb 28, 2024 → Jan 15, 2025

NCT ID
NCT06302140

About [14C]-Nanatinostat + Nanatinostat (free base) tablets in combination with Valganciclovir + Nanatinostat mesylate tablets in combination with Valganciclovir + Single-agent Nanatinostat (free base) tablets

[14C]-Nanatinostat + Nanatinostat (free base) tablets in combination with Valganciclovir + Nanatinostat mesylate tablets in combination with Valganciclovir + Single-agent Nanatinostat (free base) tablets is a phase 1 stage product being developed by Viracta Therapeutics for Advanced Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT06302140. Target conditions include Advanced Cancer.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06302140Phase 1Terminated

Competing Products

20 competing products in Advanced Cancer

See all competitors
ProductCompanyStageHype Score
AK-105AkesoPhase 1
32
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
pegfilgrastim + LY2523355Eli LillyPhase 1
33
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
BT1718Bicycle TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
IMC-18F1Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
LY3434172Eli LillyPhase 1
33
ACR-2316Acrivon TherapeuticsPhase 1
25
BBP-398LianBioPhase 1
25

Other Products from Viracta Therapeutics

Nanatinostat in combination with valganciclovirPhase 2
44
Nanatinostat + Valganciclovir + PembrolizumabPhase 1
25